HepCBC Mission Statement

HepCBC is a non-profit organization run by and for people infected and affected by hepatitis C. Our mission is to provide education, prevention and support to those living with HCV.

The Best of the Week to You: August 4 - August 11, 2017

twin epidemics

Hot Off The Press!

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection

VOSEVI is the First Once-Daily, Single Tablet HCV Regimen for Re-Treatment, and Completes Gilead's Portfolio of Sofosbuvir-Based HCV Direct-Acting Antiviral Treatments MISSISSAUGA, ON, Aug. 17, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance for VOSEVI™ (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, a pan-genotypic single-tablet regimen for the treatment o

AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes

MAVIRET is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*1 The approval is supported by a 97 percent (n=639/657) cure** rate across GT1-6 patients without cirrhosis and who are new to treatment2 MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease MONTREAL, Aug. 17, 2017 /CNW/ - AbbVie (NYSE: ABBV), a glo...

How Do Direct-Acting Antivirals for Hepatitis C Affect the Risk for Hepatocellular Carcinoma?

Hepatocellular carcinoma (HCC), which has an annual incidence rate of 1%-4%, is a potential complication of hepatitis C virus (HCV) cirrhosis owing to a multistep carcinogenesis pathway. Previous HCV treatment with interferon was associated with poor cure rates and was limited to individuals with early fibrosis or well-compensated cirrhosis. Such therapy, however, also led to a decrease in HCC after a sustained viral response (SVR). Although remarkable pro

Direct-acting Antivirals Effective in Older Patients with Hepatitis C

Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials. "Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote. Satapathy